Department of Medicine, Faculty of Medicine and Dentistry, University of Alberta, Edmonton, Canada.
Faculty of Pharmacy and Pharmaceutical Sciences, University of Alberta, Edmonton, Canada.
Curr Cardiol Rev. 2022;18(6):e110522204572. doi: 10.2174/1573403X18666220511114443.
Diabetes is a major risk factor for developing cardiovascular disease. Patients with both diabetes and cardiovascular disease have even higher mortality. The convergence of cardiology and diabetology therapy is an important step in treating patients and advancing research.
Major landmark trials and meta-analyses involving Sodium Glucose Cotransporter 2 inhibitors have shown dramatic clinical cardiorenal benefits in patients both with and without type 2 diabetes. In type 2 diabetes patients, Glucagon-like peptide-1 receptor agonists have been shown to improve major cardiac outcomes.
This hot topic of research and clinical use of glucose lowering drugs intersects the fields of cardiovascular, renal, and diabetic medicine. The numerous cardiorenal benefits have led to the rapid adoption in clinical guidelines of these glucose lowering drugs in patients with Type 2 diabetes, cardiovascular disease, or renal disease.
糖尿病是心血管疾病发展的主要危险因素。患有糖尿病和心血管疾病的患者死亡率更高。心脏病学和糖尿病学治疗的融合是治疗患者和推进研究的重要步骤。
涉及钠-葡萄糖共转运蛋白 2 抑制剂的主要里程碑试验和荟萃分析表明，此类药物可显著改善有或无 2 型糖尿病患者的临床心肾获益。在 2 型糖尿病患者中，胰高血糖素样肽-1 受体激动剂已被证明可改善主要心脏结局。
这一研究和临床应用降糖药物的热点问题涉及心血管、肾脏和糖尿病医学领域。这些降糖药物在心肾获益方面具有诸多优势，因此已迅速被 2 型糖尿病、心血管疾病或肾脏疾病患者的临床指南采纳。
